Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Breast 2

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 757Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 447Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 184Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Advanced Solid Tumors (Excluding Breast Cancer) × Clear all
NCT01867879 2024-09-05

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
44 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01874522 2024-09-05

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Taiho Oncology, Inc.

Phase 1 Completed
46 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡